We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


SYGNIS Signs Non-Exclusive Distribution Agreement with SOPACHEM

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "SYGNIS Signs Non-Exclusive Distribution Agreement with SOPACHEM"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

SYGNIS AG has announced a distribution agreement with SOPACHEM for the commercialization of the TruePrime™ product family developed by SYGNIS and designed for whole genome amplification (WGA) in Belgium.

Under the terms of the agreement, SOPACHEM will promote, market, sell and support TruePrime™ products for primer-free WGA in Belgium. TruePrime™ is based on SYGNIS’ revolutionary novel multiple displacement amplification (MDA) technology addressing key challenges in NGS applications, increasingly demanded in fields such as oncology, pathology and clinical diagnostics.

SOPACHEM is a specialized distributor with a strong focus on life sciences, diagnostics, biobanking and analytical applications with a broad portfolio of innovative products and technologies for NGS, polymerase chain reaction (PCR) analysis, DNA extraction and purification, transfection, bio-imaging and instrumentation. Besides its headquarters in Belgium, SOPACHEM runs additional offices in the Netherlands and in Luxembourg.

TruePrime™ WGA products are available in two formats, containing 25 or 100 reactions. Beside the worldwide commercialization via a fast growing list of leading international distribution partners, the product is made available and can also be directly ordered through SYGNIS’ own TruePrime™ online shop under www.sygnis.com/shop.